Our key business segments well positioned for growth: CS Muralidharan, Sun Pharma

​However, our outlook on speciality products remains very positive and I expect our existing products will continue to grow. Even in the current quarter, we saw good growth in Ilumya, Cequa, Winlevi and Odomzo. And as such, we do not see any concern for growth front.